Immunologic Research

, Volume 58, Issue 2, pp 387–393

Leukotrienes in pulmonary arterial hypertension

  • Wen Tian
  • Xinguo Jiang
  • Yon K. Sung
  • Jin Qian
  • Ke Yuan
  • Mark R. Nicolls
IMMUNOLOGY AT STANFORD UNIVERSITY

DOI: 10.1007/s12026-014-8492-5

Cite this article as:
Tian, W., Jiang, X., Sung, Y.K. et al. Immunol Res (2014) 58: 387. doi:10.1007/s12026-014-8492-5

Abstract

Leukotrienes (LTs) are lipid mediators derived from the 5-lipoxygenase (5-LO) pathway of arachidonic acid metabolism and are markers and mediators of pulmonary inflammation. Research over the past two decades has established that LTs modulate inflammation in pulmonary arterial hypertension (PAH). The purpose of this review was to summarize the current knowledge of LTs in the pathophysiology of PAH and to highlight a recent study that advances our understanding of how leukotriene B4 (LTB4) specifically contributes to pulmonary vascular remodeling. The results of these studies suggest that pharmacological inhibition of LT pathways, especially LTB4, has high potential for the treatment of PAH.

Keywords

Leukotriene Pulmonary arterial hypertension Vascular remodeling Inflammation 5-Lipoxygenase 

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Wen Tian
    • 1
  • Xinguo Jiang
    • 1
  • Yon K. Sung
    • 1
  • Jin Qian
    • 1
  • Ke Yuan
    • 2
  • Mark R. Nicolls
    • 1
  1. 1.VA Palo Alto Health Care SystemStanford UniversityPalo AltoUSA
  2. 2.Stanford University School of MedicineStanfordUSA